Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Abeona Therapeutics Inc.NASDAQ: ABEO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $9.56M fell 3.9% year over year, ahead of the -28.8% change in trailing-twelve-month research & development. Sequentially, it rose 42.4% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.
Context
- Research & development amounted to 460.7% of revenue in FY2025.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -3.9% holds above the trailing-twelve-month pace of -28.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 26.81M USD
- Year-over-year change
- -22.0%
- 4-year CAGR
- -8.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.81M | -22.0% |
| FY2024 | 2024-12-31 | 34.36M | +10.5% |
| FY2023 | 2023-12-31 | 31.09M | +7.3% |
| FY2022 | 2022-12-31 | 28.97M | -25.2% |
| FY2021 | 2021-12-31 | 38.73M | — |
Research & Development vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 research & development of $26.43M is the lowest of the 10 companies compared; the peer median is $69.93M.
- Its year-over-year change of -28.8% is the 8th highest of 10, against a peer median of -9.4%.
- Research & development amounts to 181.7% of revenue for ABEO, versus a peer median of 290.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $69.93M | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $68M | +23.2% | +5.9% | 29.9% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $62.37M | -24.6% | -10.1% | 27721.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $30.71M | -36.7% | +16.2% | — |
| LTM Mar 2026 | $26.43M | -28.8% | -2.5% | 181.7% | |
| Peer median (excluding ABEO) | $69.93M | -9.4% | +3.1% | 290.9% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Cost of Revenue | 0 | 450K | 1.61M | 2.91M | 1.53M |
| Gross Profit | 3M | 964K | 1.9M | (2.91M) | 4.29M |
| Gross Margin | 100.0% | 68.2% | 54.1% | — | 73.7% |
| Research & Development | 38.73M | 28.97M | 31.09M | 34.36M | 26.81M |
| Selling, General & Admin | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| Operating Expenses | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBITDA | (76.82M) | (34.38M) | (50.57M) | (56.62M) | 78.59M |
| EBITDA Margin | -2560.5% | -2431.6% | -1444.9% | — | 1350.3% |
| Operating Income | (89.84M) | (50.92M) | (47.14M) | (64.21M) | (89.45M) |
| Operating Margin | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Interest Income | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income / Expenses | 4.9M | 11.22M | (7.05M) | 477K | 160.73M |
| Income Before Tax | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.28M |
| Pre-Tax Margin | -2831.2% | -2807.4% | -1548.2% | — | 1224.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 100K |
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Net Margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (Basic) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 |
| EPS (Diluted) | (21.50) | (5.53) | (2.53) | (1.55) | 1.01 |
| Weighted Avg Shares | 3.94M | 7.86M | 21.38M | 41.05M | 52.95M |
| Weighted Avg Shares (Diluted) | 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.